Neuland Laboratories Limited
NSE: NEULANDLAB BSE: NEULANDLAB
NSE
13,030.00
1,286.00 (10.95%)
Prev Close
11744
Open Price
11756
Volume
539,376
Today Low / High
11756 / 13250
52 WK Low / High
6176.6 / 18100
Range
12,379 - 13,682
BSE
13,037.25
1,283.05 (10.92%)
Prev Close
11754.2
Open Price
11754.55
Volume
37,536
Today Low / High
11754 / 13249.95
52 WK Low / High
6175.6 / 18089.55
Range
12,385 - 13,689
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 13030 (target range: 12,379 - 13,682), reflecting a change of 1286 (10.95027%). On the BSE, it is listed at 13037.25 (target range: 12,385 - 13,689), showing a change of 1283.05 (10.91567%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
06 Jun
11,756.00
10.84%
05 Jun
11,817.00
-0.62%
04 Jun
11,817.00
-0.20%
03 Jun
11,670.00
1.28%
02 Jun
11,520.00
1.34%
30 May
11,255.00
2.20%
29 May
11,119.00
1.00%
28 May
11,181.00
-1.05%
27 May
11,348.00
-2.05%
26 May
11,156.00
1.49%
23 May
11,280.00
-1.10%
22 May
11,170.00
0.21%
21 May
11,195.00
-0.01%
20 May
11,226.00
-0.67%
19 May
11,076.00
1.28%
16 May
11,050.00
0.05%
15 May
12,564.00
-5.61%
14 May
12,640.00
-1.31%
13 May
12,569.00
0.14%
12 May
12,605.00
-0.29%
09 May
12,050.00
3.15%
Neuland Laboratories Limited Graph
Neuland Laboratories Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Neuland Laboratories Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 13,030.00, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 13,037.25 | 13,167.62 | 11,850.86 - 14,484.38 |
| 13,298.00 | 10,638.40 - 15,957.59 | ||
| 13,428.37 | 9,399.86 - 17,456.88 | ||
| Bearish Scenario | 13,037.25 | 12,906.88 | 11,616.19 - 14,197.57 |
| 12,776.51 | 10,221.20 - 15,331.81 | ||
| 12,646.13 | 8,852.29 - 16,439.97 |
Overview of Neuland Laboratories Limited
ISIN
INE794A01010
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
46,277
Market Cap
167,173,597,000
Last Dividend
14
Official Website
IPO Date
2008-10-13
DCF Diff
-671.00
DCF
13,701
Financial Ratios Every Investor Needs
Stock Dividend of NEULANDLAB
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-07-18 | July 18, 25 | 12 | 12 | 2025-07-18 | 2025-08-29 | |
| 2024-07-12 | July 12, 24 | 14 | 14 | 2024-07-12 | 2024-08-30 | |
| 2023-07-11 | July 11, 23 | 10 | 10 | 2023-07-11 | 2023-08-26 | |
| 2022-07-14 | July 14, 22 | 5 | 5 | 2022-07-15 | 2022-09-01 | |
| 2021-06-29 | June 29, 21 | 3 | 3 | 2021-06-30 | 2021-08-03 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 1,558.58 Cr | 733.80 Cr | 824.78 Cr | 0.5292 | 43.50 Cr | 30.92 Cr | 531.81 Cr | 300.08 Cr | 233.89 | 474.82 Cr | 0.1925 |
| 2023-03-31 | 1,160.90 Cr | 613.79 Cr | 547.11 Cr | 0.4713 | 27.76 Cr | 29.89 Cr | 234.34 Cr | 163.52 Cr | 127.45 | 279.18 Cr | 0.1409 |
| 2022-03-31 | 923.33 Cr | 553.50 Cr | 369.83 Cr | 0.4005 | 0.36 Cr | 15.69 Cr | 96.09 Cr | 63.82 Cr | 49.74 | 140.40 Cr | 0.0691 |
| 2021-03-31 | 918.18 Cr | 554.72 Cr | 363.46 Cr | 0.3958 | 21.07 Cr | 13.49 Cr | 109.63 Cr | 80.63 Cr | 62.85 | 162.91 Cr | 0.0878 |
| 2020-03-31 | 764.03 Cr | 477.79 Cr | 286.23 Cr | 0.3746 | 0.00 Cr | 14.80 Cr | 73.60 Cr | 16.21 Cr | 12.63 | 100.36 Cr | 0.0212 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 87.58 Cr | 1,832.56 Cr | 549.86 Cr | 1,282.7048 Cr | 95.39 Cr | 7.81 Cr | 350.42 Cr | 568.61 Cr | 81.17 Cr | 0.00 Cr | 13.76 Cr | 427.6832 Cr |
| 2023-03-31 | 45.42 Cr | 1,579.76 Cr | 585.67 Cr | 994.0965 Cr | 128.45 Cr | 83.03 Cr | 279.23 Cr | 498.00 Cr | 136.56 Cr | 0.00 Cr | 0.00 Cr | 438.9570 Cr |
| 2022-03-31 | 5.09 Cr | 1,383.49 Cr | 542.99 Cr | 840.5008 Cr | 240.53 Cr | 235.44 Cr | 265.21 Cr | 486.58 Cr | 0.00 Cr | 0.00 Cr | 0.50 Cr | 363.1566 Cr |
| 2021-03-31 | 2.44 Cr | 1,324.79 Cr | 538.33 Cr | 786.4577 Cr | 182.29 Cr | 179.86 Cr | 247.61 Cr | 431.23 Cr | 63.61 Cr | 0.03 Cr | -7.68 Cr | 368.5109 Cr |
| 2020-03-31 | 11.20 Cr | 1,230.98 Cr | 521.02 Cr | 709.9577 Cr | 263.73 Cr | 252.53 Cr | 219.55 Cr | 365.22 Cr | 21.67 Cr | 20.28 Cr | -3.84 Cr | 357.6337 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 261.1767 Cr | -149.6868 Cr | -69.2818 Cr | 117.5069 Cr | 42.1595 Cr | 87.5754 Cr | -143.6698 Cr | 300.0789 Cr | -39.4402 Cr | -12.8299 Cr | -71.1885 Cr |
| 2023-03-31 | 237.2119 Cr | -61.4985 Cr | -135.7956 Cr | 171.0834 Cr | 40.3245 Cr | 45.4159 Cr | -66.1285 Cr | 215.2129 Cr | -113.5815 Cr | -6.4149 Cr | -14.0233 Cr |
| 2022-03-31 | 60.3888 Cr | -95.5163 Cr | 37.7215 Cr | -37.2972 Cr | 2.6558 Cr | 5.0914 Cr | -97.6860 Cr | 82.1625 Cr | 20.3341 Cr | -3.8490 Cr | -17.6024 Cr |
| 2021-03-31 | 189.3617 Cr | -84.4237 Cr | -113.6604 Cr | 83.9647 Cr | -8.7679 Cr | 2.4356 Cr | -105.3970 Cr | 105.3335 Cr | -89.6629 Cr | -2.5660 Cr | -28.0603 Cr |
| 2020-03-31 | 57.3412 Cr | -48.6796 Cr | -5.4804 Cr | 8.5444 Cr | 3.2658 Cr | 11.2035 Cr | -48.7968 Cr | 52.9225 Cr | 7.4821 Cr | -4.9495 Cr | -26.8932 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 398.03 Cr | 205.72 Cr | 192.31 Cr | 0.4831 | 70.30 Cr | 101.59 Cr | 79.18 | 146.28 Cr | 0.2552 |
| 2024-09-30 | 310.84 Cr | 159.76 Cr | 151.09 Cr | 0.4861 | 46.15 Cr | 32.84 Cr | 25.60 | 66.56 Cr | 0.1057 |
| 2024-06-30 | 439.60 Cr | 302.46 Cr | 137.15 Cr | 0.3120 | 107.08 Cr | 97.87 Cr | 76.28 | 148.79 Cr | 0.2226 |
| 2024-03-31 | 385.01 Cr | 180.02 Cr | 204.99 Cr | 0.5324 | 90.45 Cr | 67.56 Cr | 52.66 | 109.35 Cr | 0.1755 |
| 2023-12-31 | 392.83 Cr | 178.59 Cr | 214.24 Cr | 0.5454 | 106.12 Cr | 81.39 Cr | 63.44 | 123.37 Cr | 0.2072 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 72.47 Cr | 125.03 Cr | 197.51 Cr | 305.93 Cr | 386.46 Cr | 966.48 Cr | 669.99 Cr | 1,943.80 Cr | 548.59 Cr |
| 2024-06-30 | -87.58 Cr | 175.15 Cr | 87.58 Cr | 0.00 Cr | 0.00 Cr | 87.58 Cr | 0.00 Cr | 0.00 Cr | -1,282.70 Cr |
| 2024-03-31 | 87.58 Cr | 15.01 Cr | 102.59 Cr | 375.99 Cr | 350.42 Cr | 921.08 Cr | 568.61 Cr | 1,832.56 Cr | 549.86 Cr |
| 2023-12-31 | -136.54 Cr | 273.09 Cr | 136.54 Cr | 0.00 Cr | 0.00 Cr | 136.54 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 125.01 Cr | 16.72 Cr | 141.72 Cr | 324.90 Cr | 296.28 Cr | 833.83 Cr | 511.73 Cr | 1,665.06 Cr | 532.28 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | 97.87 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 67.56 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 81.39 Cr | 30.29 Cr | 0.00 Cr | 0.00 Cr | 30.29 Cr | 166.83 Cr | 136.54 Cr | 0.00 Cr | 30.29 Cr |
| 2023-09-30 | 89.25 Cr | 29.02 Cr | 0.00 Cr | 0.00 Cr | 29.02 Cr | 136.54 Cr | 107.53 Cr | 0.00 Cr | 29.02 Cr |
| 2023-06-30 | 61.88 Cr | 27.17 Cr | 0.00 Cr | 0.00 Cr | 27.17 Cr | 72.70 Cr | 45.53 Cr | 0.00 Cr | 27.17 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2014-08-13 | August 13, 14 | 523:500 |
| 2012-03-21 | March 21, 12 | 289:250 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,679.20 | ₹4,028,870,976,000.00 | ₹2,500,031.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,544.50 | ₹1,737,361,870,500.00 | ₹361,018.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,320.90 | ₹1,100,458,988,118.00 | ₹2,158,463.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,154.30 | ₹1,067,557,063,500.00 | ₹86,576.00 |
| Mankind Pharma Limited | MANKIND | ₹2,352.40 | ₹970,767,378,020.00 | ₹353,197.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹960.15 | ₹966,131,734,500.00 | ₹810,089.00 |
| Lupin Limited | LUPIN | ₹1,999.60 | ₹913,207,322,000.00 | ₹1,289,535.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,161.10 | ₹674,369,202,200.00 | ₹392,642.00 |
| Alkem Laboratories Limited | ALKEM | ₹4,862.50 | ₹581,384,812,500.00 | ₹181,782.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,590.20 | ₹448,756,030,200.00 | ₹940,265.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Cohance Lifesciences Limited | COHANCE | ₹1,055.10 | ₹403,646,450,141.00 | ₹209,681.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,370.90 | ₹347,802,813,600.00 | ₹594,702.00 |
| Laurus Labs Limited | LAURUSLABS | ₹642.05 | ₹346,227,388,650.00 | ₹1,658,718.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,571.30 | ₹321,186,225,600.00 | ₹84,218.00 |
| Piramal Enterprises Limited | PEL | ₹1,173.70 | ₹266,051,968,600.00 | ₹1,087,297.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,702.30 | ₹265,322,180,300.00 | ₹62,791.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,790.00 | ₹244,750,000,000.00 | ₹123,199.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,505.40 | ₹244,595,886,600.00 | ₹803,276.00 |
| Eris Lifesciences Limited | ERIS | ₹1,638.30 | ₹223,111,885,500.00 | ₹55,563.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹987.60 | ₹194,125,618,800.00 | ₹40,498.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,140.00 | ₹181,580,340,000.00 | ₹116,733.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,030.00 | ₹167,173,597,000.00 | ₹539,376.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,093.30 | ₹159,115,291,610.00 | ₹64,315.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹858.30 | ₹153,730,113,000.00 | ₹354,578.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹529.95 | ₹128,536,192,800.00 | ₹485,798.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,560.50 | ₹92,300,963,700.00 | ₹8,096.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹914.45 | ₹89,424,888,505.00 | ₹310,698.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹909.25 | ₹82,409,528,235.00 | ₹242,116.00 |
| Strides Pharma Science Limited | STAR | ₹782.30 | ₹72,098,880,210.00 | ₹430,298.00 |
| FDC Limited | FDC | ₹429.20 | ₹69,878,052,000.00 | ₹308,089.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹165.55 | ₹53,724,617,100.00 | ₹2,347,837.00 |
| Innova Captab Limited | INNOVACAP | ₹889.10 | ₹50,878,685,263.00 | ₹72,505.00 |
| Suven Life Sciences Limited | SUVEN | ₹221.19 | ₹48,235,788,060.00 | ₹1,475,325.00 |
| Sequent Scientific Limited | SEQUENT | ₹187.85 | ₹47,019,230,700.00 | ₹442,806.00 |
| Hikal Limited | HIKAL | ₹372.35 | ₹45,911,127,350.00 | ₹154,610.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹462.15 | ₹42,180,430,500.00 | ₹112,178.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹592.90 | ₹41,743,598,820.00 | ₹18,878.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹368.10 | ₹36,912,331,800.00 | ₹50,918.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹718.15 | ₹36,423,921,665.00 | ₹149,821.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,141.70 | ₹35,421,576,300.00 | ₹12,390.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹64.12 | ₹35,134,810,480.00 | ₹2,840,731.00 |
| Alembic Limited | ALEMBICLTD | ₹112.07 | ₹28,777,558,628.00 | ₹591,652.00 |
| IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹88.74 | ₹26,047,585,980.00 | ₹1,118,303.00 |
| Indoco Remedies Limited | INDOCO | ₹275.10 | ₹25,377,397,290.00 | ₹25,198.00 |
Key Executives
Company Secretary & Compliance Officer
Ms. Sarada Bhamidipati
Gender: female
Year Born:
Chief Financial Officer
Mr. Abhijit Majumdar
Gender: male
Year Born:
Executive Chairman & Chief Promoter and Member of Scientific Advisory Board
Dr. Davuluri Rama Mohan Rao
Gender: Not Specified
Year Born: 1944
Chief Scientific Officer & Member of Scientific Advisory Board
Dr. Sharadsrikar Venkatesan Kotturi
Gender: Not Specified
Year Born:
Chief Human Resources Officer
Mr. Hemchandra Peruvelli
Gender: male
Year Born: 1972
Vice Chairman & Chief Executive Officer
Mr. Davuluri Sucheth Rao
Gender: male
Year Born: 1975
President of Business Development & Contract Manufacturing
Mr. Shashank Mahashabde
Gender: male
Year Born:
Chief Procurement Officer
Mr. N. Sundar
Gender: male
Year Born: 1968
Vice Chairman & MD
Mr. Davuluri Saharsh Rao
Gender: male
Year Born: 1979
Senior Vice President of Global Head Sales & BD
Mr. Sudheer Yarabolu
Gender: male
Year Born:
FAQs about Neuland Laboratories Limited
Who is the CEO of the company?
The CEO is Mr. Davuluri Sucheth Rao.
What is the current market price of the stock?
The current price is ₹13,030.00.
What is the 52-week price range?
The range is ₹6176.6-18100.
What is the market capitalization of the company?
The market capitalization is ₹16,717.36 crores.
What is the dividend yield?
The dividend yield is 0.11%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 55.75.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Neuland Laboratories Limited (ISIN: INE794A01010) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹16,717.36 crores and an average daily volume of 46,277 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹14.